tradingkey.logo
tradingkey.logo
Search

Premarket Movers | American Eagle Soars 24%; Credo Jumps 13%; Asana Gains 10%; Sanofi Falls 9%

TigerSep 4, 2025 9:02 AM
facebooktwitterlinkedin
View all comments(0)

American Eagle Outfitters shares jumped 24% in premarket trading on Thursday.

American Eagle Outfitters forecast third-quarter comparable sales above expectations on Wednesday, signaling a demand boost in the fall season from its Sydney Sweeney and Travis Kelce partnerships.

Its shares surged as the company hailed the controversial "Great Jeans" campaign with actress Sydney Sweeney, which included a fall denim collection, as a success.

Credo Technology Group Holding Ltd reported better-than-expected earnings results on Wednesday afternoon. Its shares were up 13% in premarket trading on Thursday.

The company reported fiscal first-quarter adjusted earnings per share of 52 cents, compared to Wall Street’s consensus estimate of 36 cents, according to FactSet. Revenue came in at $223.1 million, or up 274% year-over-year, which was above analysts’ expectations of $190.6 million.

Credo’s outlook was also strong. For the current quarter, it forecast a sales range with $235 million at the midpoint versus the $201.9 million consensus analyst estimate.

Asana, Inc. shares rose 10% premarket after the company reported second-quarter EPS of $0.06, better than the analyst estimate of $0.05. Revenue for the quarter came in at $196.9M versus the consensus estimate of $193.04M.

Asana sees FY 2026 EPS of $0.23-$0.25 versus the analyst consensus of $0.23.

Asana sees FY 2026 revenue of $780.00M-$790.00M versus the analyst consensus of $782.00M.

Sanofi SA fell 9% in premarket trading on Thursday after the company said its amlitelimab experimental drug met all main goals in a late-stage clinical trial with eczema patients.

The French pharmaceutical company said Thursday that amlitelimab showed efficacy in skin clearance and disease severity compared to placebo in a phase 3 study with adolescent and adults with eczema, also known as atopic dermatitis. The drug’s efficacy increased progressively throughout the treatment period, the company added.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.